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Background: Malaria is a major health and socio-economical problem in tropical and sub-tropical areas of the
world. Several methodologies have been used to assess parasite viability during the adaption of field strains to
culture or the assessment of drug potential, but these are in general not able to provide an accurate real-time
assessment of whether parasites are alive or dead.
Methods: Different commercial dyes and kits were assessed for their potential to allow for the real-time detection
of whether a blood stage malaria parasite is dead or alive.
Results: Here, a methodology is presented based on the potential-sensitive mitochondrial probe JC-1, which allows
for the real-time visualization of live (red staining) and/or dead (absence of red staining) blood stage parasites
in vitro and ex vivo. This method is applicable across malaria parasite species and strains and allows to visualize all
parasite blood stages including gametocytes. Further, this methodology has been assessed also for use in drug
sensitivity testing.
Conclusions: The JC-1 staining approach is a versatile methodology that can be used to assess parasite viability
during the adaptation of field samples to culture and during drug treatment. It was found to hold promise in the
assessment of drugs expected to lead to delayed death phenotypes and it currently being evaluated as a method
for the assessment of parasite viability during the adaptation of patient-derived Plasmodium vivax to long-term
in vitro culture.Background
Malaria, a disease caused by apicomplexan parasites of
the genus Plasmodium, with Plasmodium falciparum
causing 250–500 million clinical cases and up to 1.2
million deaths every year, is a major health- and socio-
economical problem in the tropical and sub-tropical
areas of the world [1]. Today, malaria occurs in 90
countries: an estimated 1.26 billion people (29% of the
world’s population) live in areas where malaria is cur-
rently on the rise, while 400 million people live with en-
demic malaria unchanged by current control measures
[2]. While vector and transmission control measures
(e.g. bed nets) are in place in most of the risk countries
[3,4] and the world’s scientific community is looking for
effective vaccines [5], drugs are the weapon of choice
both for malaria prophylaxis [6,7] and treatment [8,9].* Correspondence: kocken@bprc.nl
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reproduction in any medium, provided the orAs the focus shifted towards malaria eradication, there
is a need to adapt new field strains and additional pa-
rasite species. For example, Plasmodium vivax, the se-
cond most important human malaria, has been largely
neglected due to absence of in vitro culture systems and
there is an increasing need to adapt it to long-term
in vitro culture for research purposes and develop new
therapies. In addition, there are challenges derived from
the rapidly spreading resistance to existing anti-malarial
drugs, mainly in P. falciparum and from the need to tackle
emerging zoonoses (e.g. Plasmodium knowlesi [10,11]).
Thus, the search for potent anti-malarials with innovative
mechanism of action remains a priority.
The challenges inherent to the adaptation of field strains
to culture, to the development of currently lacking, in-
novative, continuous parasite culture methods for specific
malaria parasite species (e.g. P. vivax or the closely related
primate malaria Plasmodium cynomolgi and to in vivo,
ex vivo and in vitro drug potency studies would benefit
from the availability of a sensitive and specific live-deadtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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real time parasite viability.
A number of ex vivo and in vitro reference methods
have been established for the screening of anti-malarial
activity, whereby drug potency is usually expressed as
the concentration required to inhibit parasite growth by
50% (IC50). The Mark III WHO Giemsa thick blood
smear method [12] is the gold standard in the field,
while a variety of medium- to high-throughput drug
screening methods based on either nucleic acid incor-
poration of radio-labelled hypoxanthine [13], SYBR
green I dye [14,15], the detection of parasite specific en-
zymes (HRP-2 [16,17], LDH [18-20]) or the use of trans-
genic fluorescent parasites [21] have been introduced for
laboratory use. Other screening methods are pathway
specific and have been used to determine whether a
compound can interfere with a certain specific parasite
metabolic pathway (e.g. haemozoin formation [20,22]).
Drawbacks of these methods include, but are not limited
to, the subjective nature of the measurement, its repro-
ducibility, the use of radioactive material, and the need
for dedicated spaces, specialized equipment and specific
disposal procedures.
Here, a methodology is presented based on the po-
tential-sensitive mitochondrial probe JC-1, which allows
for the real-time visualization of live (red staining) and/
or dead (absence of red staining) parasites in vitro and
ex vivo. This method is applicable across parasite spe-
cies and strains (P. falciparum FCR3 and NF54, P.
knowlesi H, P. cynomolgi M) and allows visualizing all
parasite blood stages including gametocytes. This me-
thodology has been assessed also for use in drug sen-
sitivity testing and it is currently being evaluated as a
method for the assessment of parasite viability during
the adaptation of patient-derived P. vivax to long-
term in vitro culture.
Methods
Parasites
Plasmodium falciparum NF54, FCR3 strains and P.
knowlesi H strain were cultured in vitro in human A +
red blood cells (RBC) (P. falciparum) (Sanquin Blood
Bank, The Netherlands) or in rhesus monkey RBC
(P. knowlesi) in complete medium composed of RPMI-
1640 (with 25 mM HEPES, Invitrogen) supplemented
with gentamycin and 10%-20% human serum (A+) in
standard gassed (5% O2, 5% CO2, 90% N2) culture flasks
and kept under shaking in an incubator at 37°C [23-25].
Parasites for live/dead staining were obtained at a para-
sitaemia between 3-10%, stained with JC-1 as reported
below and immediately evaluated with a fluorescence
microscope (Nikon Microphot-FXA equipped with green
filter XF22, blue filter UV, red/green XF53, red XF40
and a Nikon FX35 PX camera).Plasmodium cynomolgi ex vivo samples were obtained
from infected rhesus monkeys from unrelated experi-
ments after ethical permission from the ethical commit-
tee as required under Dutch law. Blood containing P.
cynomolgi M strain trophozoite and gametocyte stages
at around 2% parasitaemia was collected, immediately
stained with JC-1 (using the protocol reported below)
and the staining was evaluated as described above.
Parasite staining with JC-1 and drug assays using LDH or
JC-1 staining as read-out
Drug assays were performed in culture flasks or 96-well
plates by adding serial drug dilutions to synchronized P.
falciparum or P. knowlesi ring-stage cultures as previously
described [13,26,27]. Briefly, the concentration range in
each of the JC-1 assays was based on the IC50 values, pre-
viously obtained using pLDH and hypoxanthine radio-
active testing for each drug on the specific parasite strain.
From stock solutions of each drug, 10-fold serial dilutions
were made and plated in triplicate. As a read out of
drug activity either the established pLDH enzymatic assay
[18,19] or JC-1 staining were used.
For JC-1 staining for fluorescent microscope-based
counting and parasite visualization, a 200 μl sample was
taken from a standard culture or ex vivo experiment,
spun down at 930 × g for 10 min at RT and medium
was removed. When drug testing was carried out in
plates, the plate was spun down and the medium re-
moved. Pellets containing parasite infected erythrocytes
were washed five times with sterile PBS at RT and re-
suspend at 5% haematocrit and 1% parasitaemia in
500 μl (plate: 100 μl) Ringer’s solution either contai-
ning 4 nM DAPI (for manual counting of slides,
Nikon microphot-FXA microscope) or 10 μl/ml Hoechst,
Bisbenzimide H 33258 (Sigma, for counting with a high-
content imager, the Operetta®, Perkin Elmer). Five μl JC-1
dye (Molecular Probes, Invitrogen) was added to the sam-
ple (final concentration: 2 μM), which was then incubated
for 30 minutes at 37°C in the dark with continuous agita-
tion. After the incubation period, cells were washed again
5 times with PBS to remove excess dye. Samples were
either used to make wet slides (manual counting) or re-
suspended in 1 mL PBS and aliquoted as specified below
for Operetta based counting.
In infected RBC containing both living and dead
parasite, the JC-1 staining is characterized by a diffused
green fluorescence (JC-1 monomer) across the RBC and
parasite’s cytoplasm. Living parasites are further charac-
terized by strong red mitochondrial fluorescence as the
JC-1 monomer aggregates in presence of the mitochon-
drial membrane potential characteristic of a living para-
site. This red signal is absent in dead parasites, which
have lost their mitochondrial functionality and thus also
their mitochondrial membrane potential.
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cence microscope. Up to 50 parasites/slide were coun-
ted. If fewer than 50 parasites were seen in slides
from drug-treated samples, we assumed the remainder
had died and lysed, and they were, therefore, noted as
dead.
Operetta® based counting was performed as follows:
after plated parasites were JC-1 stained and re-sus-
pended in 1 ml PBS as described above, 50 μl of the
suspension was transferred to a 96-well plate and an
additional 50 μl PBS was added. The positive control
containing untreated parasites was plated twice, each in
triplicate, once at the start of the plate and once at the
end to ensure consistency. RBCs were allowed to settle
for about 5 min and a snapshot of the wells was taken
using the bright-field filter to check for the cell density
in each well. If the cells could be viewed individually
the density was considered appropriate for fluorescence
measurement, otherwise the RBC suspension was ad-
justed appropriately. In order to achieve accurate coun-
ting, pictures of 25 fields per well were taken on which
all red (JC-1 aggregate) and green (JC-1 monomer only)
parasites were afterwards counted manually. Manual
counting was preferred, as Operetta counts of non-ad-
herent cells would require development and validation
of new algorithms, which were beyond the scope of our
study. Operetta settings used for making the pictures
were selected as follows: 40× long Working Distance ob-
jective, excitation 50%, transmission 50%. Visualization
of the different dyes was performed using the standard
Operetta® filters for DAPI, Texas Red and JC-1 pH8
monomer (green). Both gamma and contrast settings
were optimized to achieve optimal pictures for assessing
the status of the parasites. The intensity values used
to name a parasite alive, dying or dead are <350 units
dead, >350 < 450 units dying and >450 units alive. These
units were validated by conducting side-by-side experi-
ments using the red channel of a fluorescent microscope
to evaluate the staining’s correlation with parasite via-
bility: signal absent (parasite dead), faint red signal at
times difficult to detect (parasite dying), signal bright
red (parasite alive).
All parasites in each well were counted and their state
(living, dead, dying) assessed. The untreated controls
were used to calculate the final percent inhibition
using the formula below. If there were fewer parasites
present in the treated well as compared to the mean
untreated control, the missing parasites were assessed
as dead.%inhibition ¼ 100 Number living parasites=total nuð
%living parasites in
Results and discussion
JC1 is a viability stain distinguishing living from dead
malaria parasites
This study aimed at developing a fluorescent parasite
staining protocol that would allow to distinguish live
from dead parasites during the adaptation to long-term
in vitro culture of Plasmodium species, and would also
be useful in drug-efficacy assays. For this, we evaluated
dyes with differential membrane permeability and/or
specifically labelling parasite organelles key to life. Nu-
clear stains tested in P. falciparum and P. knowlesi
included SYTO-16, a combination of SYTO-10 and eth-
idium homodimer-2 and combinations of potential in-
sensitive anionic and cationic dyes (acridine orange with
ethidium bromide or propidium iodide), while mito-
chondrial stains tested in P. falciparum and P. knowlesi
included MitoTrack, TMRE and the potential-sensitive
Mitoprobe JC-1.
Nuclear dyes (e.g. SYTO-16) used to distinguish live
from apoptotic/necrotic eukaryotic cells have different
permeability characteristics (neutral or ionic) and staining
thus depends on the integrity of the plasma membrane.
However, when these dyes are applied to P. falciparum-
and P. knowlesi-infected RBCs, mature schizonts are sys-
tematically stained as dead, due to the increased mem-
brane permeability of the late Plasmodium blood life-cycle
stages. Although staining selectivity was observed with dyes
of the SYTO family in the case of rings, trophozoites and
free merozoites (Additional file 1 and Additional file 2),
these dyes were not considered useful for our applications.
In 1998, Borel et al. [28,29] described a new metho-
dology employing a combination of an anionic and a
cationic dye (acridine orange/ethidium bromide or bis-
benzimide (Hoechst 33258)/propidium iodide) to dis-
tinguish living from dead Toxoplasma gondii. While
acridine orange has been evaluated in the field as an al-
ternative to Giemsa for malaria diagnosis [29-31] and
found to be promising, the double dye method did not
yield consistent results when P. falciparum or P. know-
lesi drug-treated blood stage cultures were examined for
the number of living and dead parasites. This may be
due to the fact that this method is also partially based
on differential membrane permeability, as the Hoechst,
Bisbenzimide H 33258 (Sigma) dye is able to reach the
nucleus when the cell membrane is intact by passive dif-
fusion, while propidium iodide only reaches the nucleus
when the membrane is compromised. This yields the
same problem for mature schizonts as discussed above.
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fected blood cultures, which gave a bright red labelling
of living parasites, but gave at times residual vacuolar
staining in dead parasites. Another mitochondrial stain,
the potential-sensitive Mitoprobe JC-1, responds to the
difference in mitochondrial membrane potential in living
and dead cells. When the mitochondrial potential is
normal (living parasite) the dye aggregates in the mito-
chondrion, labelling the mitochondrion red; when the
potential is disrupted less of the dye aggregates resulting
in a faint red signal (dying parasite), which may at times
be difficult to detect, while when the potential is absent
(dead parasite) the dye is only present in its monomeric
form in the cytoplasm, thus labelling the parasite cyto-
plasm green. The fluorescent JC-1 staining of in vitro
cultured living P. falciparum parasites growing in human
RBC was evaluated in different parasite stages across
the blood stage life cycle (rings, trophozoites, schizonts,
merozoites and gametocytes, Figure 1). This demon-
strated that all blood stage parasites could be clearly
distinguished. Importantly, also mature schizont stages
are stained as live parasites, unlike the other staining
procedures mentioned above as JC-1 staining is notFigure 1 Living P. falciparum parasite stages stained with JC-1. Plasmo
gametocytes) stained with JC-1. The first panel in each row shows the stain
panel shows JC-1 monomer visible at 488 nm (green channel), which colou
visible at 568 nm (red channel) staining the parasite’s active mitochondriondependent on parasite membrane permeability, but only
on the mitochondrial membrane potential, which is not
altered in schizonts. In living P. falciparum parasites, the
JC-1 red staining pattern corresponds to a previously
reported pattern in which the malarial mitochondrion
was labelled with Discosoma red fluorescent protein
(DsRed) [32] or yellow fluorescent protein (YFP) [33].
JC-1 staining of a P. falciparum culture containing both
living and dead parasites demonstrated that living, dying
and dead parasites can be easily distinguished (Figure 2),
confirming that this staining method is suitable for our
purpose.
Optimization of the JC-1 staining protocol
Next we evaluated different JC-1 staining conditions:
wet, live versus dry, fixed staining, extensive versus limited
washing before and after staining, different wash media
(Ringers, RPMI, PBS) and different incubation times. The
most optimal conditions found, measured at 5% haemato-
crit and 1% parasitaemia to be: i) wet slides of standard
cultures (reduces the bleaching); ii) extensive washing with
PBS to get rid of all serum residues, as serum interferes
with the staining procedure; iii) incubation of the washeddium falciparum blood stages (rings, trophozoites, schizonts and
ing of the parasite’s nucleus with Hoechst dye (350 nm); the second
rs the parasite’s cytoplasm; the third panel shows the JC-1 aggregate
; while the last panel shows the corresponding bright field image.
Figure 2 Living, dead and dying P. falciparum schizonts stained with JC-1. JC-1 staining of Plasmodium falciparum schizonts. The first row of
images shows a living parasite as can be appreciated by the bright red signal at 568 nm indicating a functioning mitochondrion; the second row
of images shows a dead parasite killed using anti-malarial drugs (no signal at 568 nm). In the third series only a faint red signal (sometimes
difficult to detect) can be seen at 568 nm indicating that the mitochondrion membrane potential is disrupted and the parasite is dying.





Gold Standard = Giemsa 947 1053
JC-1 981 1019
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of JC-1 dye at a final concentration of 2 μM and iv) exten-
sive washing with PBS after staining to remove excess
JC-1 thereby reducing the background. For the final mi-
croscopical analysis, cells need to be re-suspended in PBS
as Ringers interferes with the detection. The preparations
need to be studied immediately after staining to prevent
parasites in PBS dying over time or the staining fading
with time and/or during prolonged exposure to fluores-
cent light sources. In general, the nuclear stain allows to
quickly recognize parasitized RBCs; the presence of a dif-
fuse green signal defines cytoplasmic staining of any para-
site and the additional presence of a bright red signal
identifies an intact mitochondrion and thus a viable para-
site. The exclusive presence of a cytoplasmic green signal
in the absence of a red signal identifies a dead parasite de-
void of mitochondrial potential (Figure 2).
Initially, in parallel staining of drug-treated cultures
and cultures left purposefully outside the incubator
overnight with both Giemsa and JC-1 were carried out,
where Giemsa was used as a Gold standard (GS). In
brief, 2000 parasites per slide were counted each time
and classified either as live or dead. Table 1 shows repre-
sentative results of repeated, parallel slide counting. As
is apparent, slightly more living parasites are estimated
in Giemsa slides, than is actually the case when JC-1 is
used as a read out. This is probably due to the fact thatit is difficult to distinguish between live and dead in
early parasite stages stained with Giemsa.
JC-1 staining is applicable to a variety of plasmodium
species
After establishing that different life cycle stages of P.
falciparum could be successfully labelled as living, dying
or dead using the JC-1 dye, the fluorescent JC-1 staining
methodology was extended to in vitro or ex vivo cul-
tured parasites infecting different types of RBC. Figure 3
shows the staining of in vitro cultured P. knowlesi (non-
human primate and human malaria that has been adap-
ted to in vitro growth in rhesus normocytes, and ex vivo
P. cynomolgi (a P. vivax-type parasite infecting non-
human primate reticulocytes obtained from rhesus ma-
caque infections. In all cases JC-1 gave a sensitive and
specific red signal that could be clearly distinguished
from the nuclear staining signal. Living parasites were
characterized by a defined red fluorescent structure;
while a only diffused green signal was observed in dead
Figure 3 Living Plamodium knowlesi and P. cynomolgi stages stained with JC-1. JC-1 staining of additional Plasmodium spp and stages. Top
row: Plasmodium knowlesi in vitro cultured blood stage trophozoite. Middle row: Ex vivo harvested Plasmodium cynomolgi blood stage schizont.
Bottom row: P. cynomolgi salivary gland sporozoite.
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JC-1 staining procedure can be used for different Plasmo-
dium species, infecting reticulocytes or normocytes and
cultured in vitro or obtained from an in vivo infection.
The method can thus be considered widely applicable
to malaria parasite species and different developmental
stages and is therefore a useful tool for quickly monitor-
ing culture viability during the adaptation of new field
strains to in vitro growth. In particular, we are now de-
veloping this methodology further for the assessment of
parasite viability during the adaptation of patient-derived
P. vivax to long-term in vitro culture. Furthermore, the
ability to also visualize sporozoites (Figure 3, a freshly
isolated P. cynomolgi sporozoite) opens the possibility
to quickly assess viability e.g. following different cryo-
preservation protocols, before testing subsequent hepa-
tocyte invasion potential.
JC-1 staining can be used as read out in drug assays
As a second objective, the usefulness of the JC-1 staining
as a read out to assess parasite viability in drug-treated
cultures was evaluated using different prototype drugs
i.e. choloroquine (CQ, acting on the food vacuole [34]),
atovaquone (ATQ, acting on mitochondria [35]) and ar-
temisinin (ARTE, likely acting through a free radical-
based oxidant stress [36,37]). In addition we evaluated a
compound series, which targets the parasite’s phospho-
lipid synthesis pathways (G25 and albitiazolium) [38-42]
and is currently being developed for clinical use. Both
manual counting of non-fixed slides from drug-treatedparasite cultures using a fluorescence microscope and
manual counting of real-time pictures (25 fields per well)
taken from plated, drug-treated parasite cultures by an
automatic high-content imaging system (Operetta®) were
used to monitor drug action. Parasite sensitivities to any
of the above mentioned drugs either on P. falciparum or
P. knowlesi was measured using JC-1 as a read-out with
both counting methodologies and were found to yield
the typical sigmoid curve indicating a linear relationship
between drug concentration and parasite inhibition bet-
ween the threshold dose level and the plateau dose level
over a limited number of drug concentrations. Although
the developed methodology is reproducible and the inter-
experiment reproducibility is relatively high (Figure 4
Panel A), the manual counting of living non-fixed parasite
slides using a fluorescent microscope had an important
limitation. Due to the long-time needed to count each
slide (3 h for a 24 well plate drug assessment), the non-
treated control wells counted at the beginning and end of
the procedure gave different results: up to 3-5% more
dead parasites were found in the control slides counted at
the end of the experiment versus the ones counted in the
beginning. This is due to the fact that live parasites do not
like to be kept in wet slide conditions for too long. The
use of Operetta® pictures of the wells and manual coun-
ting of parasites in those pictures solved this problem:
comparison of control wells at the beginning and end in
each plate showed high (98-99%) consistency, due to the
fact that the parasites’ condition was fixed by the pictures,
which were taken in rapid succession across the whole
Figure 4 IC50 determination using JC-1 and/or pLDH in parallel
on drug treated P. falciparum cultures. Culture P. falciparum-
infected erythrocyte were incubated for 48 h in the presence of the
indicated drug concentration at haematocrit of 5% and 1%
parasitaemia. Panel A - shows that the inter-experiment variability
between 2 separate JC-1 determinations is low (red and violet lines)
and that the methodology is more accurate (IC50 is consistently
lower) than the IC50 determination obtained with the pLDH
methodology; Panel B - shows typical curves obtained by splitting
parasites derived from a same mother culture into plates, in which
they were cultured in parallel under the same environmental
conditions in the presence of rising artemisinin concentrations and
IC50 curves where either determined using the pLDH (violet line) or
the JC-1 (blue line) methodology; Panel C – shows typical curves
obtained by splitting parasites derived from a same mother culture
into plates, in which they were cultured in parallel under the same
environmental conditions in the presence of rising atovaquone
concentrations and IC50 curves where either determined using the
pLDH (violet line) or the JC-1 (blue line) methodology.
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procedure appears more sensitive than the fluorescent
microscope counting at the low (IC20) drug concentra-
tions and more accurate at high drug concentrations
(IC90) when there are only very few living parasites left as
many more fields are photographed in rapid succession
per well and counted in comparison to manually counted
slides in which a time-field counting balance needs to be
found as the amount of dead parasites in control wells in-
creases over time as explained above.
Parallel experiments using the LDH and JC-1 staining
methodologies were carried out using CQ, ATQ (Figure 4
Panel B) and ARTE (Figure 4 Panel C) treated P. falcip-
arum FCR3 and P. knowlesi cultures. Experiments were
performed in triplicate for each drug concentration.
With all three drugs, the JC-1 staining methodology ap-
pears to be more accurate as the JC-1 read out is a direct
measure of parasite viability obtained by staining the
whole parasite population (including rings) and not by
measuring a surrogate parasite marker produced only by
the trophozoite and schizont stages (pLDH or LDH en-
zyme activity). Repeated JC-1 staining experiments over
once cycle (48 h for P. falciparum and 24 h for P.
knowlesi) have on average yielded IC50s for the P. falci-
parum FCR3 and P. knowlesi H strains treated with the
different drugs, which are lower than with the LDH
methodology (Tables 2 and 3). These experiments were
repeated several times and it appears that the gain in
sensitivity over a longer life-cycle (P. falciparum: 48 h)
is in general higher than over a shorter life-cycle
(P. knowlesi: 24 h). This reflects the fact that despite
the lethal effect exerted by the drugs, the production
of the malaria-specific pLDH protein is not stopped
rapidly and the measurement of the pLDH protein,
which is still being synthesized by the parasite thus
biases this type of test. However, the JC1 staining re-
flects the mitochondrial status of the parasite at the
time when the test is applied.
Choline analogues G25 and albitiazolium constitute a
new class of anti-malarial drugs that target the malarial
membrane biogenesis through the phospholipid metabo-
lism. The clinical candidate albitiazolium (formerly named
T3 and SAR97276) [42] is currently evaluated in clinical
phase II trials to treat severe malaria by the parenteral
route. Choline analogues give unreliable IC50 results,
when assayed with the traditional LDH test [43]. ItTable 2 IC50 ranges from in parallel experiments
Drug CQ in nM* ATQ in nM* ARTE in nM*
Assay LDH JC-1 LDH JC-1 LDH JC-1
Pf FCR3 14.1-16.6 8.8-10.9 0.7-1.3 0.5-0.9 0.1-0.9 0.03-0.1
Pk H 9.38-10.9 7.8-9.7 2-2.6 2.1-2.7 1.1-1.6 0.8-1.2
*All IC50 ranges were determined on an average of 8–10 experiments where
JC-1 and LDH experiments were carried out side by side.
Table 3 IC50 average with standard deviation
Drug in nM* Assay Pf FCR3 Pk H
CQ LDH 15.71 ± 1.23 10.4 ± 1.03
JC-1 10.33 ± 0.97 8.3 ± 0.92
ATQ LDH 1.16 ± 1.41 2.54 ± 0.86
JC-1 0.78 ± 0.72 2.27 ± 0.31
ARTE LDH 0.52 ± 0.83 1.53 ± 0.46
JC-1 0.07 ± −0.59 0.95 ± 0.72
*Mean IC50s determined on an average of 8–10 experiments where JC-1 and
LDH experiments were carried out side by side.
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sence of G25 or albitiazolium [41,43,44] for a few hours
incurred in parasite disappearance in the following life
cycle. Compound potency is associated to their properties
of accumulating in a non-reversible way within the intra-
erythrocytic parasites, which irremediably impaired pa-
rasite viability while the parasite morphology is affected
more belatedly. This indicates that the drug operates
through a Trojan horse effect and its real pharmacological
effect is dissociated from the effects on parasite mor-
phology and metabolism [41,43]. Therefore, the metho-
dology was further tested to establish whether it would
be appropriate to assess these delayed parasite collapses,
by exposing both P. falciparum FCR3 (Figure 5) and P.
knowlesi H cultures to G25 and albitiazolium at their IC50
for 2 hours using CQ as a reference) [43] and followed theFigure 5 Delayed death phenotypes monitored using JC-1 on synchro
the phospholipid pathway inhibitors prototype drug. P. falciparum FCR
to 7.82 nM chloroquine and the phospholipid pathway inhibitors prototype
contact with the drugs, cell were washed and resuspended in drug-free fre
viability over the course of at least 3 cycles to detect any delayed drug effe
ring culture to the IC50 of chloroquine for 2 h has no delayed effect but ac
(blue line), but exposure of the same ring culture to the IC50 of G25 and al
which for G25 reaches 100% within the second parasite cycle (red line) andparasitaemia development into the next cycle using JC-1
as a read-out (Figure 3). The IC50s were first determined
using radio-labelled hypoxanthine [13] after exposure to
the drugs over 1 cycle, 48 h for P. falciparum and 24 h
for P. knowlesi). IC50 for P. knowlesi were 0.36 mM
(albitiazolium), 1.38 mM (G25) and 5.62 nM (CQ) re-
spectively; while the IC50s for P. falciparum were 2.25 nM
(albitiazolium), 0.6 nM (G25) and 7.82 nM (CQ) respect-
ively. When parasite were incubated with the drugs at
their IC50 for only 2 h followed by the washing out of the
drugs, a potent delayed effect of G25 on P. falciparum
FCR3 (Figure 5, red line) was found, since the full effect of
the drug (100% inhibition calculated with the formula
reported above for each time point) is observed in the se-
cond cycle (past the 24 h). Albitiazolium seems to have a
similar effect, but with a delayed collapse even into the
third cycle (Figure 5, green line), while as expected CQ
(Figure 5, blue line) has no delayed-death effect and acts
within the first cycle on trophozoites and schizonts. Re-
sults obtained with P. knowlesi H (Additional file 4) also
indicate that after incubation of the parasite with the cho-
line analogues at their IC50 for only 2 h, both G25 and
albithiazolium exerted delayed pharmacological effects
that are observed during the cycle following the contact
with the drug. Altogether, results support the conclusion
indicating that use of the JCI staining may be a suitable al-
ternative method to LDH for assessing the IC50 of com-
pounds suspected of having delayed death effects.nized P. falciparum FCR3 cultures exposed to chloroquine and
3 culture (5% hematocrit and 0.1 starting parasitaemia) were exposed
drugs (2.25 nM albitiazolium and 0.6 nM G25). After two hours of
sh complete medium. JC-1 staining was then used to monitor parasite
cts. The results are expressed as means ± SEM (n = 3). Exposure of a
ts on trophozoites and schizonts during the first cycle as expected
bitiazolium for only 2 hours results in a potent delayed death effect,
for albitiazolium probably within beyond the third (green line) cycle.
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The JC-1 staining approach is a versatile methodology
that can be used to assess parasite viability during the
adaptation of field samples to culture and during drug
treatment. On-going efforts aimed at establishing P. vivax
blood stage cultures will particularly benefit from the use
of the described method. In particular, this methodology
appears to be more accurate and reliable than Giemsa
staining of fixed parasites, which rarely gives clear quan-
titative evidence of whether a parasite culture is in good
shape or not.
In the context of the assessment of a compound’s anti-
malarial potency, this methodology offers reproducible,
robust results comparable to established methods such
as the LDH IC50 test, while being in general more accu-
rate. Furthermore, a live stain such as JC-1 offers the pos-
sibility to follow compounds overtime, thus opening the
way to the assessment of delayed death drug phenotype.Additional files
Additional file 1: P. falciparum and P. knowlesi parasites stained
with the mitochondrial dyes TMRE and Mitotrack. The mitochondrial
dye TMRE and Mitortrack appear to give rise to a very aspecific, diffused
signal when compared to a well defined signal of the potential-sensitive
mitochondrial dye JC-1 (Figures 1, 2, 3). Both TMRE and Mitotrack appear
to stain vacuoles and the cytoplasm of the parasites. This raises the
question on whether they are indeed labelling specifically the parasites’
mitochondria.
Additional file 2: Living P. falciparum and P. knowlesi parasites
stained with the nuclear Syto-16 dye and co-stained with the
mitochondrial Mitotrack dye. In eukaryotic cells, Syto-16 is used to
distinguish live (no stain) from apoptotic /necrotic cells (nuclei stained
green). The dye is able to cross the plasma membrane of the cell only if
it is compromised and thus enter the cell nucleus staining it green.
However, as Plasmodium schizonts due to their increased membrane
permeability, the Syto-16 dyes labels living schizonts as dead by staining
their nuclei green.
Additional file 3: Dead P. knowlesi parasites stained with JC-1. JC-1
staining of drug-treated Plasmodium knowlesi culture showing a dead
parasite as can be appreciated by the absence of signal at 568 nm.
Additional file 4: Delayed death phenotypes monitored using JC-1
on synchronized P. knowelsi H cultures exposed to chloroquine and
the phospholipid pathway inhibitors prototype drug. P. knowlesi H
culture (5% hematocrit and 0.1 starting parasitaemia) were exposed to
5.62 nM chloroquine and the phospholipid pathway inhibitors prototype
drugs (1.38 nM albitiazolium and 0.36 nM G25). After two hours of
contact with the drugs, cell were washed and resuspended in drug-free
fresh complete medium. JC-1 staining was then used to monitor parasite
viability over the course of at least 3 cycles to detect any delayed drug
effects. The results are expressed as means ± SEM (n = 3). Exposure of a
ring culture to the IC50 of chloroquine for 2 h has no delayed effect but
acts on trophozoites and schizonts during the first cycle as expected
(violet line), but exposure of the same ring culture to the IC50 of G25 and
albitiazolium for only 2 hours results in a potent delayed death effect,
which for G25 reaches 100% within the second parasite cycle (blue line)
and for albitiazolium probably within beyond the third (red line) cycle.Abbreviations
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